Switch theme
Sign up to access all valuation multiples
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.
2015
3
Last FY Revenue n/a
LTM EBITDA -$0.1M
$2.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Stayble Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$0.1M.
In the most recent fiscal year, Stayble Therapeutics achieved revenue of n/a and an EBITDA of -$1.3M.
Stayble Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Stayble Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$0.1M | XXX | -$1.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$0.1M | XXX | -$1.3M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | n/a | XXX | -$1.3M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Stayble Therapeutics's stock price is SEK 1 (or $0).
Stayble Therapeutics has current market cap of SEK 22.9M (or $2.4M), and EV of SEK 20.7M (or $2.1M).
See Stayble Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1M | $2.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Stayble Therapeutics has market cap of $2.4M and EV of $2.1M.
Stayble Therapeutics's trades at n/a EV/Revenue multiple, and -1.7x EV/EBITDA.
Equity research analysts estimate Stayble Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Stayble Therapeutics's P/E ratio is not available.
See valuation multiples for Stayble Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.4M | XXX | $2.4M | XXX | XXX | XXX |
| EV (current) | $2.1M | XXX | $2.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -18.2x | XXX | -1.7x | XXX | XXX | XXX |
| EV/EBIT | -18.2x | XXX | -1.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | -5.2x | XXX | -1.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialStayble Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.4M for the same period.
Stayble Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Stayble Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Stayble Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -156% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Stayble Therapeutics acquired XXX companies to date.
Last acquisition by Stayble Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Stayble Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Stayble Therapeutics founded? | Stayble Therapeutics was founded in 2015. |
| Where is Stayble Therapeutics headquartered? | Stayble Therapeutics is headquartered in Sweden. |
| How many employees does Stayble Therapeutics have? | As of today, Stayble Therapeutics has 3 employees. |
| Is Stayble Therapeutics publicy listed? | Yes, Stayble Therapeutics is a public company listed on STO. |
| What is the stock symbol of Stayble Therapeutics? | Stayble Therapeutics trades under STABL ticker. |
| When did Stayble Therapeutics go public? | Stayble Therapeutics went public in 2020. |
| Who are competitors of Stayble Therapeutics? | Similar companies to Stayble Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Stayble Therapeutics? | Stayble Therapeutics's current market cap is $2.4M |
| Is Stayble Therapeutics profitable? | Yes, Stayble Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Stayble Therapeutics? | Stayble Therapeutics's last 12 months EBITDA is -$0.1M. |
| What is the current EV/EBITDA multiple of Stayble Therapeutics? | Current EBITDA multiple of Stayble Therapeutics is -18.2x. |
| What is the current FCF of Stayble Therapeutics? | Stayble Therapeutics's last 12 months FCF is -$0.4M. |
| What is the current EV/FCF multiple of Stayble Therapeutics? | Current FCF multiple of Stayble Therapeutics is -5.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
